Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

ABSTRACT:

Purpose

Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger.

Patients and methods

We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multi

SUBMITTER: Gerson JN 

PROVIDER: S-EPMC7554677 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature